Fundamental Analysis of GRITSTONE BIO INC(NASDAQ:GRTS) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GRTS. GRTS was compared to 565 industry peers in the Biotechnology industry. GRTS may be in some trouble as it scores bad on both profitability and health. GRTS is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GRTS has reported negative net income.

In the past year GRTS has reported a negative cash flow from operations.

GRTS had negative earnings in each of the past 5 years.

In the past 5 years GRTS always reported negative operating cash flow.

1.2 Ratios

GRTS has a worse Return On Assets (-93.33%) than 75.31% of its industry peers.

GRTS has a worse Return On Equity (-599.53%) than 80.64% of its industry peers.

		Industry Rank	Sector Rank
ROA	-93.33%
ROE	-599.53%
ROIC	N/A

ROA(3y)-51.54%

ROA(5y)-50.67%

ROE(3y)-123.97%

ROE(5y)-101.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GRTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.

GRTS has more shares outstanding than it did 1 year ago.

The number of shares outstanding for GRTS has been increased compared to 5 years ago.

The debt/assets ratio for GRTS is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -9.83, we must say that GRTS is in the distress zone and has some risk of bankruptcy.

GRTS has a worse Altman-Z score (-9.83) than 75.67% of its industry peers.

GRTS has a Debt/Equity ratio of 1.83. This is a high value indicating a heavy dependency on external financing.

Looking at the Debt to Equity ratio, with a value of 1.83, GRTS is doing worse than 81.35% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	1.83
Debt/FCF	N/A
Altman-Z	-9.83

ROIC/WACCN/A

WACC7.5%

2.3 Liquidity

A Current Ratio of 2.54 indicates that GRTS has no problem at all paying its short term obligations.

With a Current ratio value of 2.54, GRTS is not doing good in the industry: 71.58% of the companies in the same industry are doing better.

GRTS has a Quick Ratio of 2.54. This indicates that GRTS is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 2.54, GRTS is not doing good in the industry: 70.34% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.54
Quick Ratio	2.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.49% over the past year.

GRTS shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.14%.

The Revenue has been growing by 68.87% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)13.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%48.39%

Revenue 1Y (TTM)25.14%

Revenue growth 3Y59.34%

Revenue growth 5Y68.87%

Sales Q2Q%-52.89%

3.2 Future

GRTS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.58% yearly.

Based on estimates for the next years, GRTS will show a very strong growth in Revenue. The Revenue will grow by 74.91% on average per year.

EPS Next Y19.29%

EPS Next 2Y8.07%

EPS Next 3Y1.48%

EPS Next 5Y16.58%

Revenue Next Year-74.34%

Revenue Next 2Y-41.42%

Revenue Next 3Y2.57%

Revenue Next 5Y74.91%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year GRTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y8.07%

EPS Next 3Y1.48%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GRTS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GRITSTONE BIO INC

NASDAQ:GRTS (10/21/2024, 8:17:44 PM)

After market: 0.026 -0.01 (-19.25%)

0.0322

-0.01 (-31.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.80M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-93.33%
ROE	-599.53%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	1.83
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.54
Quick Ratio	2.54
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)13.49%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y19.29%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)25.14%

Revenue growth 3Y59.34%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

GRITSTONE BIO INC (GRTS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens